



20 Jun 2017
20 June 2017
P.U. (A) 181

WARTA KERAJAAN PERSEKUTUAN

*FEDERAL GOVERNMENT
GAZETTE*

PERINTAH RACUN (PINDAAN SENARAI RACUN)
(NO. 3) 2017

*POISONS (AMENDMENT OF POISONS LIST)
(NO. 3) ORDER 2017*

DISIARKAN OLEH/
PUBLISHED BY
JABATAN PEGUAM NEGARA/
ATTORNEY GENERAL'S CHAMBERS

AKTA RACUN 1952

PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 3) 2017

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

Nama

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Senarai Racun) (No. 3) 2017**.

Pindaan Jadual Pertama

2. Akta Racun 1952 dipinda dalam Jadual Pertama—

(a) dalam Senarai Racun—

- (i) dengan memasukkan selepas butiran “Acetylcholine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Acetylcysteine	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C";

(ii) dengan memasukkan selepas butiran "Aflibercept" dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Afoxolaner	-	Preparations for animal treatment";				

- (iii) dengan memasukkan selepas butiran “Alfuzosin; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Alirocumab	-	All preparations”;				

- (iv) dalam butiran “Alkaloids; the following: their salts, simple or complex; their quaternary compounds:”, dengan menggantikan butiran “Mityragynine” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Mitragynine	All preparations unless in Group D	-	-		Preparations for laboratory use”;	

- (v) dengan memasukkan selepas butiran “Benzydamine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“N-Benzylpiperazine (BZP)	-	“All preparations”;				

- (vi) dengan memasukkan selepas butiran “Brinzolamide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Bromhexine	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(vii) dengan memasukkan selepas butiran “Bromocriptine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe)	-	All preparations”;				

(viii) dengan menggantikan butiran “Calcitriol” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Calcitriol	-	-	All preparations unless exempted	-	-	Product which is registered under the Control of Drugs and Cosmetics Regulations 1984 other than product for parenteral administration”;

- (ix) dengan memasukkan selepas butiran “Calcium dobesilate” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Calcium folinate	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C
Calcium gluconate	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

- (x) dengan memasukkan selepas butiran “Chlormidazole; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“2-(4-chloro-2, 5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe)	-	All preparations”;				

- (xi) dengan memasukkan selepas butiran “Cimetidine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Cimicoxib	-	All preparations”;				

- (xii) dengan memasukkan selepas butiran “Citalopram; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Citicoline	-	All preparations”;				

- (xiii) dengan memasukkan selepas butiran “Clozapine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Cobimetinib	-	All preparations”;				

(xiv) dengan memasukkan selepas butiran “Elaterin” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Electrolytes; the following: Calcium chloride Potassium chloride Sodium bicarbonate Sodium chloride Sodium lactate Potassium dihydrogen phosphate Potassium phosphate Sodium glycerophosphate Magnesium sulphate	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xv) dengan memasukkan selepas butiran “Eplerenone” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Eptacog alpha	-	All preparations”;				

(xvi) dengan memasukkan selepas butiran “Everolimus” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Evolocumab	-	All preparations”;				

(xvii) dengan memasukkan selepas butiran “Flunixin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Fluorescein sodium	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xviii) dengan memasukkan selepas butiran “Fluorides, alkali; organo fluorides” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“[1-(5-fluoropentyl)-1H-indol-3-yl] (naphthalen-1-yl) methanone (AM-2201)”	-	All preparations”;				

(xix) dengan memasukkan selepas butiran “Gabapentin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Gadolinium chelate”	-	All preparations for diagnostic or therapeutic use	-	-	-	All preparations unless in Group B”;

(xx) dengan memasukkan selepas butiran “Imatinib” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Imidafenacin	-	-	All preparations”;			

(xxi) dengan memasukkan selepas butiran “Iodine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe)	-	All preparations”;				

(xxii) dengan menggantikan butiran “Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:	All condoms, appliances or preparations containing local anaesthetics unless in Group B, Group C or Group D	All preparations in pharmaceutical dosage forms unless in Group C	All preparations in pharmaceutical dosage form for topical use in the nose, eyes and ears or external use. Suppositories, lozenges and pastilles	Preparations for laboratory use”;		

Amino-alcohols
esterified with
benzoic acid,
phenylacetic
acid,
phenylpropionic
acid, cinnamic
acid or the
derivatives of
these acids; their
salts
Benzocaine
Bupivacaine
Butyl
aminobenzoate
Cinchocaine
Diperodon
Etidocaine
Lignocaine
Levobupivacaine
Mepivacaine
Orthocaine
Oxethazaine
Phenacaine

Phenodanisyl
 Prilocaine
 Ropivacaine
 Tetracaine

(xxiii) dengan menggantikan butiran “Mannitol” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Mannitol	-	Product for diagnostic use which is registered under the Control of Drugs and Cosmetics Regulations 1984	All preparations for parenteral administration unless in Group B	-	-	All preparations unless in Group B and Group C”;

(xxiv) dengan memasukkan selepas butiran “Memantin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“Mephedrone	-	“All preparations”;					

- (xxv) dengan memasukkan selepas butiran “3, 4-Methylenedioxy- metamphetamine (MDMA)(DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“3, 4 – Methylenedioxyproval erone (MDPV)	-	All preparations”;				

- (xxvi) dengan memasukkan selepas butiran “Methylphenidate; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Methylone	-	All preparations”;				

(xxvii) dengan memasukkan selepas butiran “Naphazoline; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Naphthalen-1-yl-(1-pentyl-1H-indol-3-yl) methanone (JWH-018)	-	All preparations”;				

(xxviii) dengan menggantikan butiran “Nicotinic acid” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nicotinic acid	-	Sustained release preparations	All preparations for parenteral administration other than in Group B	-	-	All preparations unless in Group B and Group C”;

(xxix) dengan memasukkan selepas butiran “Pantoprazole; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Paracetamol	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xxx) dengan memasukkan selepas butiran “Pralatrexate” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Pralidoxime	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xxxii) dengan memasukkan selepas butiran “Prostaglandins and its synthetic derivatives; their salts; their esters” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Protamine sulphate	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xxxiii) dengan memasukkan selepas butiran “Ramipril” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ramucirumab	-	All preparations”;				

(xxxiii) dengan menggantikan butiran “Retinol; its esters” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Retinol; its ester	-	All preparations in pharmaceutical dosage forms for human use, containing more than 10,000 i.u. of Vitamin A per dosage unit	All preparations for parenteral administration unless in Group B	-	-	All preparations unless in Group B and Group C”;

(xxxiv) dengan memasukkan selepas butiran “Roxatidine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Rufinamide	-	All preparations”;				

(xxxv) dengan memasukkan selepas butiran “Sildenafil; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Simeprevir	-	All preparations”;				

(xxxvi) dengan memasukkan selepas butiran “Sodium cromoglycate” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Sodium edetate	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”; dan

(xxxvii) dengan memasukkan selepas butiran “Viloxazine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Vitamins; the following:	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”; dan
Alfacalcidol						
Ascorbic acid						
Cholecalciferol						
Cyanocobalamin						
Ergocalciferol						
Mecobalamin						
Panhotenic acid						
Phytomenadione						
Pyridoxine						
Riboflavin						
Thiamine						
Tocopherol						

(b) dalam Lampiran kepada Senarai Racun—

(i) dalam senarai “**Analeptics and Central Stimulants**” —

(A) dengan memasukkan selepas butiran “Meclofenoxate; its salts” butiran “Mephedrone”; dan

(B) dengan memasukkan selepas butiran “Methylenedioxyamphetamine (MDA) (DD)” butiran “Methylone”;

(ii) dalam senarai “**Analgesics including antipyretic and anti-inflammatory agents**” —

(A) dengan memasukkan selepas butiran “Alclofenac” butiran “[1-(5-fluoropentyl)-1H-indol-3-yl](naphthalen-1-yl) methanone (AM-2201)”;

(B) dengan memasukkan selepas butiran “Celecoxib” butiran “Cimicoxib”; dan

(C) dengan memasukkan selepas butiran “Nalbuphine; its salts” butiran “Naphthalen-1-yl-(1-pentyl-1H-indol-3-yl) methanone (JWH-018)”;

(iii) dalam senarai “**Anticholinergics**”, dengan memasukkan selepas butiran “Homatropine” butiran “Imidafenacin”;

(iv) dalam senarai “**Anticonvulsants**”, dengan memasukkan selepas butiran “Retigabine” butiran “Rufinamide”;

(v) dalam senarai “**Antihypertensives**”, dengan memasukkan selepas butiran “N-Methylephedrine camsylate” butiran “Moxonidine”;

(vi) dalam senarai “**Antineoplastic agents and Immunosuppressants**”—

(A) dengan memasukkan selepas butiran “Clofarabine” butiran “Cobimetinib”;

(B) dengan memasukkan selepas butiran “Raltegravir” butiran “Ramucirumab”; dan

(C) dengan memasukkan selepas butiran “Semustine; its salts” butiran “Simeprevir”;

(vii) dalam senarai “**Hallucinogens**”—

(A) dengan memasukkan selepas butiran “2-amino-1-(2, 5-dimethoxy-4-methyl) phenylpropane or STP or DOM (DD)” butiran yang berikut:

“2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe)

2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe)”;

- (B) dengan memasukkan selepas butiran “Eticyclidine or PCE; its salts (DD)” butiran “2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe)”;
- (viii) dalam senarai “**Industrial and laboratory poisons**”, dengan memasukkan selepas butiran “Anthranilic acid; its salts” butiran “N-Benzylpiperazine (BZP)”;
- (ix) dalam senarai “**Miscellaneous**”—
- (A) dengan memasukkan selepas butiran “Acarbose” butiran “Acetylcysteine”;
- (B) dengan memasukkan selepas butiran “Aflibercept” butiran “Afoxolaner”;
- (C) dengan memasukkan selepas butiran “Alfuzosin; its salts” butiran “Alirocumab”;
- (D) dengan memasukkan selepas butiran “Brinzolamide” butiran “Bromhexine”;
- (E) dengan memasukkan selepas butiran “Calcium dobesilate” butiran yang berikut:
- “Calcium folinate
- Calcium gluconate”;

(F) dengan memasukkan selepas butiran “Chenodeoxycholic acid” butiran “Cholestyramine”;

(G) dengan memasukkan selepas butiran “Cisapride” butiran “Citicoline”;

(H) dengan memotong butiran “Cholestyramine”;

(I) dengan memasukkan selepas butiran “Elaterin” butiran yang berikut:

“Electrolytes; the following:

Calcium chloride
Potassium chloride
Sodium bicarbonate
Sodium chloride
Sodium lactate
Potassium dihydrogen phosphate
Potassium phosphate
Sodium glycerophosphate
Magnesium sulphate”;

(J) dengan memasukkan selepas butiran “Eltrombopag” butiran “Eptacog alpha”;

(K) dengan memasukkan selepas butiran “Etidronate disodium” butiran “Evolocumab”;

- (L) dengan memasukkan selepas butiran “Flumazenil” butiran “Fluorescein sodium”;
- (M) dengan memasukkan selepas butiran “Furazolidone” butiran “Gadolinium chelate”;
- (N) dengan memasukkan selepas butiran “Methyl bromide” butiran “3, 4 -Methylenedioxyprovalerone (MDPV)”;
- (O) dengan memasukkan selepas butiran “Palanasetron” butiran “Paracetamol”;
- (P) dengan memasukkan selepas butiran “Polymethylene bistrimethylammonium salts” butiran “Pralidoxime”;
- (Q) dengan memasukkan selepas butiran “Prostaglandins and its synthetic derivatives; their salts; their esters” butiran “Protamine sulphate”;
- (R) dengan memasukkan selepas butiran “Sodium cromoglycate” butiran “Sodium edetate”; dan
- (S) dengan memasukkan selepas butiran “Verteporfin” butiran yang berikut:

“Vitamins; the following:

- Alfacalcidol
- Ascorbic acid
- Cholecalciferol
- Cyanocobalamin
- Ergocalciferol
- Mecobalamin
- Panhotenic acid
- Phytomenadione
- Pyridoxine

Riboflavin
Thiamine
Tocopherol”.

Dibuat 6 Jun 2017
[KK(R)608(14); PN(PU2)172/XII]

DATUK SERI DR. S. SUBRAMANIAM
Menteri Kesihatan

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) (NO. 3) ORDER 2017

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order:

Citation

1. This order may be cited as the **Poisons (Amendment of Poisons List) (No. 3) Order 2017**.

Amendment of First Schedule

2. The Poisons Act 1952 is amended in the First Schedule —

(a) in the Poisons List—

(i) by inserting after the item “Acetylcholine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Acetylcysteine	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(ii) by inserting after the item “Aflibercept” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Afoxolaner	-	Preparations for animal treatment”;				

(iii) by inserting after the item “Alfuzosin; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Alirocumab	-	All preparations”;				

- (iv) in the item “Alkaloids; the following: their salts, simple or complex; their quaternary compounds:”, by substituting for the item “Mitragynine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Mitragynine	All preparations unless in Group D	-	-	Preparations for laboratory use”;		

- (v) by inserting after the item “Benzydamine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“N-Benzylpiperazine (BZP)	-	All preparations”;				

- (vi) by inserting after the item “Brinzolamide” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Bromhexine	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(vii) by inserting after the item “Bromocriptine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe)	-	All preparations”;				

(viii) by substituting for the item “Calcitriol” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Calcitriol	-	-	All preparations unless exempted	-	-	Product which is registered under the Control of Drugs and Cosmetics Regulations 1984 other than product for parenteral administration”;

(ix) by inserting after the item “Calcium dobesilate” and the particulars relating to it the following items:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Calcium folinate	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C
Calcium gluconate	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(x) by inserting after the item “Chlormidazole; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe)	-	All preparations”;				

(xi) by inserting after the item “Cimetidine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Cimicoxib	-	All preparations”;				

(xii) by inserting after the item “Citalopram; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Citicoline	-	All preparations”;				

(xiii) by inserting after the item “Clozapine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Cobimetinib	-	All preparations”;				

(xiv) by inserting after the item “Elaterin” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Electrolytes; the following: Calcium chloride Potassium chloride Sodium bicarbonate Sodium chloride Sodium lactate Potassium dihydrogen phosphate Potassium phosphate Sodium glycerophosphate Magnesium sulphate”.	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xv) by inserting after the item “Eplerenone” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Eptacog alpha	-	All preparations”;				

(xvi) by inserting after the item “Everolimus” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Evolocumab	-	All preparations”;				

(xvii) by inserting after the item “Flunixin” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Fluorescein sodium	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xviii) by inserting after the item “Fluorides, alkali; organo fluorides” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“[1-(5-fluoropentyl)-1H-indol-3-yl](naphthalen-1-yl) methanone (AM-2201)	-	All preparations”;				

(xix) by inserting after the item “Gabapentin” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Gadolinium chelate	-	All preparations for diagnostic or therapeutic use	-	-	-	All preparations unless in Group B”;

(xx) by inserting after the item “Imatinib” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Imidafenacin	-	-	All preparations”;			

(xxi) by inserting after the item “Iodine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe)	-	All preparations”;				

(xxii) by substituting for the item “Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:	All condoms, appliances or preparations containing local anaesthetics unless in Group B, Group C or Group D	All preparations in pharmaceutical dosage forms unless in Group C	All preparations in pharmaceutical dosage form for topical use in the nose, eyes and ears or external use. Suppositories, lozenges and pastilles	Preparations for laboratory use”;		

Amino-alcohols
esterified with
benzoic acid,
phenylacetic
acid,
phenylpropionic
acid, cinnamic
acid or the
derivatives of
these acids; their
salts
Benzocaine
Bupivacaine
Butyl
aminobenzoate
Cinchocaine
Diperodon
Etidocaine
Lignocaine
Levobupivacaine
Mepivacaine
Orthocaine
Oxethazaine
Phenacaine
Phenodanisyl

Prilocaine
Ropivacaine
Tetracaine

(xxiii) by substituting for the item “Mannitol” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Mannitol	-	Product for diagnostic use which is registered under the Control of Drugs and Cosmetics Regulations 1984	All preparations for parenteral administration unless in Group B	-	-	All preparations unless in Group B and Group C”;

(xxiv) by inserting after the item “Memantin” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“Mephedrone	-	All preparations”;					

(xxv) by inserting after the item “3, 4-Methylenedioxy- metamphetamine (MDMA)(DD)” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“3, 4 – Methylenedioxypropyl amphetamine (MDPV)”	-	All preparations”;				

(xxvi) by inserting after the item “Methylphenidate; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Methylone	-	All preparations”;				

(xxvii) by inserting after the item “Naphazoline; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Naphthalen-1-yl-(1- pentyl-1H-indol-3-yl) methanone (JWH-018)”	-	All preparations”;				

(xxviii) by substituting for the item “Nicotinic acid” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nicotinic acid	-	Sustained release preparations	All preparations for parenteral administration other than in Group B	-	-	All preparations unless in Group B and Group C”;

(xxix) by inserting after the item “Pantoprazole; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Paracetamol	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xxx) by inserting after the item “Pralatrexate” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Pralidoxime	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xxxi) by inserting after the item “Prostaglandins and its synthetic derivatives; their salts; their esters” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Protamine sulphate	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”;

(xxxii) by inserting after the item “Ramipril” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ramucirumab	-	All preparations”;				

(xxxiii) by substituting for the item “Retinol; its esters” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Retinol; its ester	-	All preparations in pharmaceutical dosage forms for human use, containing more than 10,000 i.u. of Vitamin A per dosage unit	All preparations for parenteral administration unless in Group B	-	-	All preparations unless in Group B and Group C”;

(xxxiv) by inserting after the item “Roxatidine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Rufinamide	-	All preparations”;				

(xxxv) by inserting after the item “Sildenafil; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Simeprevir	-	All preparations”;				

(xxxvi) by inserting after the item “Sodium cromoglycate” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Sodium edetate	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”; and

(xxxvii) by inserting after the item “Viloxazine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Vitamin; the following:	-	-	All preparations for parenteral administration	-	-	All preparations unless in Group C”; and
Alfacalcidol						
Ascorbic acid						
Cholecalciferol						
Cyanocobalamin						
Ergocalciferol						
Mecobalamin						
Panhotenic acid						
Phytomenadione						
Pyridoxine						
Riboflavin						
Thiamine						
Tocopherol						

(b) in the Appendix to the Poisons List—

(i) in the list of “**Analeptics and Central Stimulants**” —

(A) by inserting after the item “Meclofenoxate; its salts” the item “Mephedrone”; and

(B) by inserting after the item “Methylenedioxyamphetamine (MDA) (DD)” the item “Methylone”;

(ii) in the list of “**Analgesics including antipyretic and anti-inflammatory agents**” —

(A) by inserting after the item “Alclofenac” the item “[1-(5-fluoropentyl)-1H-indol-3-yl](naphthalen-1-yl)methanone (AM-2201)”;

(B) by inserting after the item “Celecoxib” the item “Cimicoxib”; and

(C) by inserting after the item “Nalbuphine; its salts” the item “Naphthalen-1-yl-(1-pentyl-1H-indol-3-yl) methanone (JWH-018)”;

(iii) in the list of “**Anticholinergics**”, by inserting after the item “Homatropine” the item “Imidafenacin”;

(iv) in the list of “**Anticonvulsants**”, by inserting after the item “Retigabine” the item “Rufinamide”;

- (v) in the list of “**Antihypertensives**”, by inserting after the item “N-Methylephedrine camsylate” the item “Moxonidine”;

- (vi) in the list of “**Antineoplastic agents and Immunosuppressants**”—
 - (A) by inserting after the item “Clofarabine” the item “Cobimetinib”;

 - (B) by inserting after the item “Raltegravir” the item “Ramucirumab”; and

 - (C) by inserting after the item “Semustine; its salts” the item “Simeprevir”;

- (vii) in the list of “**Hallucinogens**”—
 - (A) by inserting after the item “2-amino-1-(2, 5-dimethoxy-4-methyl) phenylpropane or STP or DOM (DD)” the following items:
 - “2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe)

 - 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe)”;

(B) by inserting after the item “Eticyclidine or PCE; its salts (DD)” the item “2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; (25I-NBOMe)”;

(viii) in the list of “**Industrial and laboratory poisons**” by inserting after the item “Anthranilic acid; its salts” butiran “N-Benzylpiperazine (BZP)”;

(ix) in the list of “**Miscellaneous**”—

(A) by inserting after the item “Acarbose” the item “Acetylcysteine”;

(B) by inserting after the item “Aflibercept” the item “Afoxolaner”;

(C) by inserting after the item “Alfuzosin; its salts” the item “Alirocumab”;

(D) by inserting after the item “Brinzolamide” the item “Bromhexine”;

(E) by inserting after the item “Calcium dobesilate” the following items:

“Calcium folinate

Calcium gluconate”;

(F) by inserting after the item “Chenodeoxycholic acid” the item “Cholestyramine”;

(G) by inserting after the item “Cisapride” the item “Citicoline”;

(H) by deleting the item “Cholestyramine”;

(I) by inserting after the item “Elaterin” the following item:

“Electrolytes; the following:

Calcium chloride

Potassium chloride

Sodium bicarbonate

Sodium chloride

Sodium lactate

Potassium dihydrogen phosphate

Potassium phosphate

Sodium glycerophosphate

Magnesium sulphate”;

(J) by inserting after the item “Eltrombopag” the item “Eptacog alpha”;

(K) by inserting after the item “Etidronate disodium” the item “Evolocumab”;

(L) by inserting after the item “Flumazenil” the item “Fluorescein sodium”;

(M) by inserting after the item “Furazolidone” the item “Gadolinium chelate”;

(N) by inserting after the item “Methyl bromide” the item “3, 4 -Methylenedioxyprovalerone (MDPV)”;

(O) by inserting after the item “Palanosetron” the item “Paracetamol”;

(P) by inserting after the item “Polymethylene bistrimethylammonium salts” the item “Pralidoxime”;

(Q) by inserting after the item “Prostaglandins and its synthetic derivatives; their salts; their esters” the item “Protamine sulphate”;

(R) by inserting after the item “Sodium cromoglycate” the item “Sodium edetate”; and

(S) by inserting after the item “Verteporfin” the following item:

“Vitamins; the following:

Alfacalcidol
Ascorbic acid
Cholecalciferol
Cyanocobalamin
Ergocalciferol
Mecobalamin
Panthotenic acid
Phytomenadione
Pyridoxine
Riboflavin
Thiamine
Tocopherol”.

Made 6 June 2017
[KK(R)608(14); PN(PU2)172/XII]

DATUK SERI DR. S. SUBRAMANIAM
Minister of Health